 | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | VEGF-A, angiopoietin 2[1] |
| Clinical data | |
| Trade names | Vabysmo |
| Other names | RO6867461; RG7716; faricimab-svoa |
| License data | |
| Pregnancy category | |
| Routes of administration | Intravitreal |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6506H9968N1724O1026S45 |
| Molar mass | 130197.05 g·mol−1 |
Faricimab, sold under the brand name Vabysmo, is a monoclonal antibody used for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).[1][8] Faricimab is the first bispecific monoclonal antibody[9] to target both vascular endothelial growth factor (VEGF)[1] and angiopoietin 2 (Ang-2).[1] By targeting these pathways, faricimab stabilizes blood vessels in the retina.[9] It is given by intravitreal injection (injection into the eye) by an ophthalmologist.[1]
Faricimab was developed by Roche in Penzberg (Roche Innovation Center Munich).[10] Faricimab was approved for medical use in the United States in January 2022,[8][11] and in the European Union in September 2022.[7]
- ^ a b c d e f "Vabysmo- faricimab injection, solution". DailyMed. 7 February 2022. Archived from the original on 21 February 2022. Retrieved 20 February 2022.
- ^ a b "Vabysmo". Therapeutic Goods Administration (TGA). 9 November 2022. Retrieved 29 April 2023.
- ^ "Updates to the Prescribing Medicines in Pregnancy database". Therapeutic Goods Administration (TGA). 21 December 2022. Archived from the original on 3 April 2022. Retrieved 2 January 2023.
- ^ "Vabysmo (Roche Products Pty Ltd)". Therapeutic Goods Administration (TGA). 28 September 2022. Archived from the original on 13 October 2022. Retrieved 29 April 2023.
- ^ "Summary Basis of Decision - Vabysmo". Health Canada. 31 August 2022. Archived from the original on 29 September 2022. Retrieved 29 September 2022.
- ^ "Vabysmo Product information". Health Canada. 25 April 2012. Archived from the original on 1 October 2022. Retrieved 30 September 2022.
- ^ a b Cite error: The named reference
Vabysmo EPARwas invoked but never defined (see the help page). - ^ a b "FDA approves Roche's Vabysmo, the first bispecific antibody for the eye, to treat two leading causes of vision loss" (Press release). Roche. 31 January 2022. Archived from the original on 31 January 2022. Retrieved 31 January 2022.
- ^ a b Nicolò M, Ferro Desideri L, Vagge A, Traverso CE (March 2021). "Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases". Expert Opinion on Investigational Drugs. 30 (3): 193–200. doi:10.1080/13543784.2021.1879791. PMID 33471572. S2CID 231665201.
- ^ "Neue Netzhaut-Therapie aus Penzberg". www.merkur.de (in German). 2 September 2023. Retrieved 12 August 2024.
- ^ "FDA approves faricimab for treatment of wet AMD, DME". Ophthalmology Times. 28 January 2022. Archived from the original on 29 January 2022. Retrieved 29 January 2022.